{
  "pmcid": "6389380",
  "sha256": "565b61de7832fc0c4904acf3cf2ed63680f2117be544771f5fd8734623c31e17",
  "timestamp_utc": "2025-11-09T22:50:15.932625+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.1498219895288,
    "reading_ease": 16.294959860383955,
    "word_count": 191
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Low Molecular Weight Dextran Sulfate in Islet Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Twenty-four subjects were randomized to receive either LMW-DS or heparin during islet transplantation."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study evaluates the efficacy and safety of low molecular weight dextran sulfate (LMW-DS) compared to heparin in preventing IBMIR."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy and safety of low molecular weight dextran sulfate (LMW-DS) compared to heparin in preventing IBMIR."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was stimulated C-peptide response measured 75±5 days post-transplant."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was not implemented due to the open-label design."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Twelve participants were randomized to each group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The primary outcome showed no significant difference between LMW-DS and heparin (1.33±1.10 vs. 1.56±1.36 ng/mL, p=0.66)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, primarily related to immunosuppression."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}